CD274 and non-small cell lung carcinoma: Meanwhile, NSCLC patients occasionally display a type III tumor environment when PD-L1 is expressed constitutively on cancer cells through oncogenic signaling; they are unlikely to respond to single-agent anti-PD-1/PD-L1 treatment [42].